insulin sensitivity Inhibitors
1 drugsAbout insulin sensitivity
Insulin sensitivity reflects how efficiently cells respond to insulin, influencing glucose uptake and blood sugar regulation. Reduced insulin sensitivity, or insulin resistance, is a hallmark of metabolic disorders like type 2 diabetes.
While direct genetic evidence linking insulin sensitivity to specific diseases is unavailable, its crucial role in glucose metabolism makes it a key therapeutic target. Improving insulin sensitivity can help manage diabetes and potentially prevent its progression.
Currently, one FDA-approved drug, XIGDUO XR (small molecule), targets insulin sensitivity for metabolic indications. AstraZeneca is the sole company with an approved drug in this space.
Top insulin sensitivity Drugs
AstraZeneca is the only company with an approved drug targeting insulin sensitivity.
Low competition suggests high entry barriers or untapped market potential for new entrants.
insulin sensitivity Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets insulin sensitivity, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches.
insulin sensitivity Clinical Trials 422 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on insulin sensitivity. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 68 | 52 | 5 | 11 | 91% |
| Phase 2 | 96 | 45 | 12 | 39 | 79% |
| Phase 3 | 116 | 73 | 3 | 39 | 96% |
| Phase 4 | 142 | 90 | 13 | 38 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved insulin sensitivity drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting insulin sensitivity. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
insulin sensitivity Drug Approval Timeline (2014 - 2014)
The first and only drug, XIGDUO XR, was approved in 2014.
The lack of recent approvals indicates potential saturation or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 206 (27 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on insulin sensitivity. A trial counts if an approved drug acting on insulin sensitivity is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.